Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions

Journal of Virology

Volumn 89, Issue 8, 2015, Pages 4681-4684

  Anstett, Kaitlin ^a,b   Mesplede, Thibault ^a   Oliveira, Maureen ^a   Cutillas, Vincent ^a,b   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; MUTANT PROTEIN; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN NL4.3); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IC50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; TISSUE CULTURE; VIRUS INFECTIVITY; VIRUS MUTATION; DRUG RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MUTAGENESIS, SITE-DIRECTED;

EID: 84925424676     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03485-14     Document Type: Article

References (14)

1. Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N Engl J Med 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
2. Shafer RW. 2006. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194(Suppl 1):S51-S58. http://dx.doi.org/10.1086/505356.
3. Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, Almond S, St Clair M, Flack N, Min S. 2012. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naïve adults: 96-week results from SPRING-1 (ING112276), abstr 102LB. 19th CROI, Conf Retrovir Opportunistic Infect, Seattle, WA.
4. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
5. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10:22. http://dx.doi.org/10.1186/1742-4690-10-22.
6. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
7. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207:740-748. http://dx.doi.org/10.1093/infdis/jis750.
8. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
9. Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. 2014. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 69:2733-2740. http://dx.doi.org/10.1093/jac/dku199.
10. Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. 2014. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 28:813-819. http://dx.doi.org/10.1097/QAD.0000000000000199.
11. Oliveira M, Brenner BG, Wainberg MA. 2009. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol 485:427-433. http://dx.doi.org/10.1007/978-1-59745-170-3_29.
12. Hurt CB, Sebastian J, Hicks CB, Eron JJ. 2014. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 58:423-431. http://dx.doi.org/10.1093/cid/cit697.
13. Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M. 2014. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 70:405-411. http://dx.doi.org/10.1093/jac/dku387.
14. Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M, Walter H. 2014. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc 17(Suppl 3):19749. http://dx.doi.org/10.7448/IAS.17.4.19749.